Crohn’s disease
Conditions
Interventions
Sponsors
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients whose clinical diagnosis is consistent with CD; (2) Age 16-75 years old; (3) Patients whose disease is in remission (CDAI<150); (4) Patients whose disease has relapsed more than twice in the past year; (5) Not taking the drug or taking one or more of the following drugs: [Mesalazine (<=4g/d), prednisone (<=15mg/d), azathioprine (<=1mg/kg/d)] ; And prednisone and mesalamine have been taken for at least one month, and azathioprine has been taken for at least 3 months; (5) Those who have not used biological agents within 3 months before entering the study; (6) Those who have never had acupuncture experience; (7) Patients who understand the study and sign an informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients who have recently become pregnant or are pregnant or breastfeeding; (2) Patients with severe organic disease; (3) Patients diagnosed with mental illness; (4) Patients who suffer from multiple diseases at the same time and take other drugs for a long time and may affect the observation of this clinical trial; (5) Those who have serious extraintestinal manifestations such as severe skin diseases (such as erythema nodules, pyoderma gangrenosum, etc.), ocular diseases (such as iritis, uveitis, etc.), thromboembolic diseases, etc.; (6) Complications such as severe intestinal fistula, abdominal abscess, intestinal stenosis and intestinal obstruction, perianal disease (perianal abscess, etc.), gastrointestinal bleeding, intestinal perforation, etc.; (7) Those who have short bowel syndrome, who have undergone abdominal or gastrointestinal surgery in the past six months; (8) Those who have skin diseases or defects in the selected area of acupuncture and moxibustion cannot be acupuncture.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence rate of patients at 24 weeks; | — |
Secondary
| Measure | Time frame |
|---|---|
| Recurrence time and number of recurrences in 24 weeks;CDAI;IBDQ;HADS;Laboratory inspection and evaluation; | — |
Countries
China
Contacts
Public ContactHuangan Wu
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Outcome results
None listed